Communicable Disease Market: A BCC Research Overview
REPORT SCOPE:
The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
REPORT INCLUDES:
The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
REPORT INCLUDES:
- 23 data tables and 24 additional tables
- Detailed overview of the global market for communicable diseases within the healthcare industry
- Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa
- A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage
- Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace
- Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Disease Overview
HIV
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Epidemiology
Chlamydia
Epidemiology
Genital Herpes
Epidemiology
Gonorrhea
Epidemiology
Hepatitis A, B and C
Epidemiology
HPV
Syphilis
Epidemiology
Malaria
Incidence and Geographical Distribution
Tuberculosis
Incidence and Geographical Distribution
Influenza
Incidence and Mortality
Trichomoniasis
Scabies
Bacterial Vaginosis
Candidiasis
Chancroid (Venereal Ulcers)
Pediculosis Pubis
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Regional Awareness Program for Communicable Diseases
Development of Novel Therapies
Public Private Partnership
Global Program to Counter HIV
Increasing Prevalence of Communicable Diseases
Market Restraints
Social Stigma Associated with STD
High Cost of Treatment
Underestimating the Risk of Contracting the Disease
Lack of Prenatal Screenings for STD
CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE
Global Market for Communicable Disease, by Disease Indication
HIV
Market Size and Forecast
Market Analysis
Hepatitis B&C
Market Size and Forecast
Market Analysis
Herpes Simplex Virus
Market Size and Forecast
Market Analysis
Influenza
Market Size and Forecast
Market Analysis
Malaria
Market Size and Forecast
Market Analysis
Tuberculosis
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Communicable Disease, by Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Middle East & Africa
CHAPTER 7 PIPELINE ANALYSIS
Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika
CHAPTER 8 REGULATION AND REIMBURSEMENT
Regulations
U.S.
Europe
Japan
China
Pricing and Reimbursement
U.S.
Europe
Japan
CHAPTER 9 COMPETITIVE LANDSCAPE
Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
Influenza Therapeutics: Global Competitor Analysis
CHAPTER 10 COMPANY PROFILES
ABBOTT LABORATORIES
ABBVIE INC.
ASTRAZENECA/MEDIMMUNE
AUROBINDO PHARMA LTD.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CIPLA INC.
DAIICHI SANKYO
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
JANSSEN PHARMACEUTICALS, INC.
MERCK & CO., INC.
MITSUBISHI TANABE PHARMA CORP.
MYLAN LABORATORIES
NOVARTIS AG
PFIZER INC.
HOFFMANN-LA ROCHE INC.
SANOFI, SANOFI PASTEUR
SEQIRUS, A CSL COMPANY
VIIV HEALTHCARE
CHAPTER 11 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Disease Overview
HIV
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Epidemiology
Chlamydia
Epidemiology
Genital Herpes
Epidemiology
Gonorrhea
Epidemiology
Hepatitis A, B and C
Epidemiology
HPV
Syphilis
Epidemiology
Malaria
Incidence and Geographical Distribution
Tuberculosis
Incidence and Geographical Distribution
Influenza
Incidence and Mortality
Trichomoniasis
Scabies
Bacterial Vaginosis
Candidiasis
Chancroid (Venereal Ulcers)
Pediculosis Pubis
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Regional Awareness Program for Communicable Diseases
Development of Novel Therapies
Public Private Partnership
Global Program to Counter HIV
Increasing Prevalence of Communicable Diseases
Market Restraints
Social Stigma Associated with STD
High Cost of Treatment
Underestimating the Risk of Contracting the Disease
Lack of Prenatal Screenings for STD
CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE
Global Market for Communicable Disease, by Disease Indication
HIV
Market Size and Forecast
Market Analysis
Hepatitis B&C
Market Size and Forecast
Market Analysis
Herpes Simplex Virus
Market Size and Forecast
Market Analysis
Influenza
Market Size and Forecast
Market Analysis
Malaria
Market Size and Forecast
Market Analysis
Tuberculosis
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Communicable Disease, by Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Middle East & Africa
CHAPTER 7 PIPELINE ANALYSIS
Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika
CHAPTER 8 REGULATION AND REIMBURSEMENT
Regulations
U.S.
Europe
Japan
China
Pricing and Reimbursement
U.S.
Europe
Japan
CHAPTER 9 COMPETITIVE LANDSCAPE
Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
Influenza Therapeutics: Global Competitor Analysis
CHAPTER 10 COMPANY PROFILES
ABBOTT LABORATORIES
ABBVIE INC.
ASTRAZENECA/MEDIMMUNE
AUROBINDO PHARMA LTD.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CIPLA INC.
DAIICHI SANKYO
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
JANSSEN PHARMACEUTICALS, INC.
MERCK & CO., INC.
MITSUBISHI TANABE PHARMA CORP.
MYLAN LABORATORIES
NOVARTIS AG
PFIZER INC.
HOFFMANN-LA ROCHE INC.
SANOFI, SANOFI PASTEUR
SEQIRUS, A CSL COMPANY
VIIV HEALTHCARE
CHAPTER 11 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Communicable Disease Market, by Region, Through 2024
Table 1: Milestones in the History of HIV
Table 2: Life Cycle of HIV Therapeutics Target Points
Table 3: HIV Incidence, by Country, 2005-2016
Table 4: HIV Incidence, by Country, 2014-2017
Table 5: Chlamydia Incidence, by Country, 2012-2017
Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012
Table 7: Gonorrhea Epidemiology, by Country, 2012-2017
Table 8: Hepatitis A Incidence, by Country, 2012-2017
Table 9: Hepatitis B Incidence, by Country, 2012-2017
Table 10: Hepatitis C Incidence, by Country, 2012-2015
Table 11: Syphilis Incidence, by Country, 2013-2016
Table 12: Infectious Syphilis Incidence, by Country, 2012-2014
Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015
Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015
Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer
Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024
Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024
Table 20: ART Therapy Coverage, by Region, 2017
Table 21: North American Estimated HBsAG Seroprevalence, 2016
Table 22: Drug for Chlamydia Treatment
Table 23: Drug for Gonorrhea Treatment
Table 24: Global Communicable Disease Market, by Region, Through 2024
Table 25: North American Communicable Disease Market, by Country, Through 2024
Table 26: European Communicable Disease Market, by Country/Region, Through 2024
Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024
Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016
Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019
Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019
Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019
Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019
Table 33: RSV Development Pipeline and Recent Launches, 2019
Table 34: Malaria Development Pipeline and Recent Launches, 2019
Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019
Table 36: MERS Development Pipeline and Recent Launches, 2019
Table 37: Dengue Development Pipeline and Recent Launches, 2019
Table 38: Ebola Development Pipeline and Recent Launches, 2019
Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019
Table 40: Marburg Development Pipeline and Recent Launches, 2019
Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019
Table 42: Zika Development Pipeline and Recent Launches, 2019
Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019
Table 46: Acronyms Used in This Report
Summary Table: Global Communicable Disease Market, by Region, Through 2024
Table 1: Milestones in the History of HIV
Table 2: Life Cycle of HIV Therapeutics Target Points
Table 3: HIV Incidence, by Country, 2005-2016
Table 4: HIV Incidence, by Country, 2014-2017
Table 5: Chlamydia Incidence, by Country, 2012-2017
Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012
Table 7: Gonorrhea Epidemiology, by Country, 2012-2017
Table 8: Hepatitis A Incidence, by Country, 2012-2017
Table 9: Hepatitis B Incidence, by Country, 2012-2017
Table 10: Hepatitis C Incidence, by Country, 2012-2015
Table 11: Syphilis Incidence, by Country, 2013-2016
Table 12: Infectious Syphilis Incidence, by Country, 2012-2014
Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015
Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015
Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer
Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024
Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024
Table 20: ART Therapy Coverage, by Region, 2017
Table 21: North American Estimated HBsAG Seroprevalence, 2016
Table 22: Drug for Chlamydia Treatment
Table 23: Drug for Gonorrhea Treatment
Table 24: Global Communicable Disease Market, by Region, Through 2024
Table 25: North American Communicable Disease Market, by Country, Through 2024
Table 26: European Communicable Disease Market, by Country/Region, Through 2024
Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024
Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016
Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019
Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019
Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019
Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019
Table 33: RSV Development Pipeline and Recent Launches, 2019
Table 34: Malaria Development Pipeline and Recent Launches, 2019
Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019
Table 36: MERS Development Pipeline and Recent Launches, 2019
Table 37: Dengue Development Pipeline and Recent Launches, 2019
Table 38: Ebola Development Pipeline and Recent Launches, 2019
Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019
Table 40: Marburg Development Pipeline and Recent Launches, 2019
Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019
Table 42: Zika Development Pipeline and Recent Launches, 2019
Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019
Table 46: Acronyms Used in This Report
LIST OF FIGURES
Summary Figure: Global Communicable Disease Market Share, by Region, 2018
Figure 1: Types of Drug Failure Encountered During HIV Treatment
Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016
Figure 3: Estimated HIV Regional Prevalence, 2016
Figure 4: Estimated HIV Regional Incidence, 2016
Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014
Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014
Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014
Figure 9: Hepatitis Timeline, 1990-2004
Figure 10: Hepatitis Timeline, 2011-2015
Figure 11: Hepatitis Timeline, 2015-2017
Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016
Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014
Figure 14: Global Prevalence of Tuberculosis, 1990-2015
Figure 15: Global Incidence of Tuberculosis, 1990-2015
Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024
Figure 20: Global HIV Market, 2018-2024
Figure 21: Global Prevalence of HIV, by Region, 2016
Figure 22: Global Incidence of HIV, by Region, 2016
Figure 23: Global Hepatitis Market, 2018-2024
Figure 24: Global Herpes Simplex Virus Market, 2018-2024
Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022
Figure 26: Global Influenza Market, 2018-2024
Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
Figure 28: Global Malaria Market, 2018-2024
Figure 29: Global Tuberculosis Market, 2018-2024
Figure 30: Global Others Market, 2018-2024
Figure 31: Global Communicable Disease Market Share, by Region, 2018
Figure 32: North American Communicable Disease Market, 2018-2024
Figure 33: North American Communicable Disease Market Share, by Country, 2018
Figure 34: U.S. Communicable Disease Market, 2018-2024
Figure 35: Canadian Communicable Disease Market, 2018-2024
Figure 36: Mexican Communicable Disease Market, 2018-2024
Figure 37: European Communicable Disease Market Share, by Country/Region, 2018
Figure 38: German Communicable Disease Market, 2018-2024
Figure 39: French Communicable Disease Market, 2018-2024
Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015
Figure 41: French Historic and Current Gonorrhea Incidence Trend, 2011-2015
Figure 42: U.K. Communicable Disease Market, 2018-2024
Figure 43: Spanish Communicable Disease Market, 2018-2024
Figure 44: Italian Communicable Disease Market, 2018-2024
Figure 45: Rest of European Communicable Disease Market, 2018-2024
Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018
Figure 47: Japanese Communicable Disease Market, 2018-2024
Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016
Figure 49: Chinese Communicable Disease Market, 2018-2024
Figure 50: Indian Communicable Disease Market, 2018-2024
Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024
Figure 52: South American Communicable Disease Market, 2018-2024
Figure 53: Middle East and African Communicable Disease Market, 2018-2024
Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018
Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018
Summary Figure: Global Communicable Disease Market Share, by Region, 2018
Figure 1: Types of Drug Failure Encountered During HIV Treatment
Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016
Figure 3: Estimated HIV Regional Prevalence, 2016
Figure 4: Estimated HIV Regional Incidence, 2016
Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014
Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014
Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014
Figure 9: Hepatitis Timeline, 1990-2004
Figure 10: Hepatitis Timeline, 2011-2015
Figure 11: Hepatitis Timeline, 2015-2017
Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016
Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014
Figure 14: Global Prevalence of Tuberculosis, 1990-2015
Figure 15: Global Incidence of Tuberculosis, 1990-2015
Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024
Figure 20: Global HIV Market, 2018-2024
Figure 21: Global Prevalence of HIV, by Region, 2016
Figure 22: Global Incidence of HIV, by Region, 2016
Figure 23: Global Hepatitis Market, 2018-2024
Figure 24: Global Herpes Simplex Virus Market, 2018-2024
Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022
Figure 26: Global Influenza Market, 2018-2024
Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
Figure 28: Global Malaria Market, 2018-2024
Figure 29: Global Tuberculosis Market, 2018-2024
Figure 30: Global Others Market, 2018-2024
Figure 31: Global Communicable Disease Market Share, by Region, 2018
Figure 32: North American Communicable Disease Market, 2018-2024
Figure 33: North American Communicable Disease Market Share, by Country, 2018
Figure 34: U.S. Communicable Disease Market, 2018-2024
Figure 35: Canadian Communicable Disease Market, 2018-2024
Figure 36: Mexican Communicable Disease Market, 2018-2024
Figure 37: European Communicable Disease Market Share, by Country/Region, 2018
Figure 38: German Communicable Disease Market, 2018-2024
Figure 39: French Communicable Disease Market, 2018-2024
Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015
Figure 41: French Historic and Current Gonorrhea Incidence Trend, 2011-2015
Figure 42: U.K. Communicable Disease Market, 2018-2024
Figure 43: Spanish Communicable Disease Market, 2018-2024
Figure 44: Italian Communicable Disease Market, 2018-2024
Figure 45: Rest of European Communicable Disease Market, 2018-2024
Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018
Figure 47: Japanese Communicable Disease Market, 2018-2024
Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016
Figure 49: Chinese Communicable Disease Market, 2018-2024
Figure 50: Indian Communicable Disease Market, 2018-2024
Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024
Figure 52: South American Communicable Disease Market, 2018-2024
Figure 53: Middle East and African Communicable Disease Market, 2018-2024
Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018
Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018
